Drug profile · INN
elbasvir
ZEPATIER
elbasvir (ZEPATIER) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — elbasvir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
elbasvir (ZEPATIER) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Nonstructural protein 5A inhibitor
Primary target: Nonstructural protein 5A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is elbasvir?
elbasvir (ZEPATIER) is a nonstructural protein 5a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for elbasvir?
ZEPATIER is a marketed brand name for elbasvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elbasvir?
elbasvir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.